Who are AZD0120's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): ABT-712, AZD5335.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/azd0120.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

AZD0120 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

AZD0120 (AZD0120) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: FGFR1 inhibitor. Area: Oncology.

phase 3 FGFR1 inhibitor FGFR1 (Fibroblast Growth Factor Receptor 1) Oncology Biologic Live · refreshed every 30 min

Target snapshot

AZD0120 (AZD0120) — AstraZeneca. AZD0120 is a selective inhibitor of fibroblast growth factor receptor 1 (FGFR1) that blocks aberrant signaling in cancer cells dependent on FGFR1 activation.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
AZD0120 TARGET	AZD0120	AstraZeneca	phase 3	FGFR1 inhibitor	FGFR1 (Fibroblast Growth Factor Receptor 1)
ABT-712	ABT-712	AbbVie (prior sponsor, Abbott)	phase 3	FGFR1 inhibitor	FGFR1 (Fibroblast Growth Factor Receptor 1)
AZD5335	AZD5335	AstraZeneca	phase 3	FGFR1 inhibitor	FGFR1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (FGFR1 inhibitor class)

AstraZeneca · 2 drugs in this class
AbbVie (prior sponsor, Abbott) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AZD0120 — Competitive Intelligence Brief. https://druglandscape.com/ci/azd0120. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing